Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Eurand Announces Data on Switching Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency From Unapproved PEPs to FDA-Approved ZENPEP(R)
Eurand Announces Data on Switching Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency From Unapproved PEPs to FDA-Approved ZENPEP(R)
Eurand Announces Data on Switching Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency From Unapproved PEPs to FDA-Approved ZENPEP(R)
Submitted by
admin
on June 17, 2010 - 8:46am
Source:
Yahoo/MarketWire
News Tags:
Aptalis
Zenpep
exocrine pancreatic insufficiency
Headline:
Eurand Announces Data on Switching Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency From Unapproved PEPs to FDA-Approved ZENPEP(R)
Do Not Allow Advertisers to Use My Personal information
